Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1525-1528

  Androutsopoulos, Vasilis P ^a   Mahale, Sachin ^a   Arroo, Randolph R J ^a   Potter, Gerry ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Antiproliferative activity; Cell cycle arrest; CYP1 enzymes; Diosmetin; Luteolin

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DIOSMETIN; LUTEOLIN; ANTINEOPLASTIC AGENT; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME ACTIVATOR; FLAVONOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ADENOCARCINOMA; BIOTRANSFORMATION; BREAST TUMOR; CELL CYCLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY; PILOT STUDY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ENZYME ACTIVATORS; FEMALE; FLAVONOIDS; HUMANS; LUTEOLIN; PILOT PROJECTS;

EID: 67649935021     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000384     Document Type: Article

References (20)

1. Ye CL, Liu Y and Wei DZ: Antioxidant and anticancer activity of 3′-formyl-4′, 6′-dihydroxy-2′-methoxy-5′-methylchalcone and (2S)-8-formyl-5-hydroxy-7-methoxy-6-methylflavanone. J Pharm Pharmacol 59: 553-559, 2007.
2. Granado-Serrano AB, Martín MA, Bravo L, Goya L and Ramos S: Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr 136: 2715-2721, 2006.
3. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V and Kong AN: Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch Pharmaceut Res 8: 633-644, 2006.
4. Androutsopoulos V, Arroo RR, Hall JF, Surichan S and Potter GA: Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB 468 human breast cancer cells due to CYP1 mediated metabolism. Breast Cancer Res 10: R39, 2008.
5. Atherton K, Mutch E and Ford D: Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem Pharmacol 72: 624-631, 2006.
6. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA and Burke MD: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
7. McFadyen MCE, Melvin WT and Murray GI: Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 3: 363-371, 2004.
8. Kadifkova Panovska T, Kulevanova S and Stefova M: In vitro antioxidant activity of some Teucrium species (Lamiaceae). Acta Pharm 55: 207-214, 2005.
9. Meirinhos J, Silva BM, Valentío P, Seabra RM, Pereira JA, Dias A, Andrade PB and Ferreres F: Analysis and quantification of flavonoidic compounds from Portuguese olive (Olea europaea L.) leaf cultivars. Nat Prod Res 19: 189-195, 2005.
10. Androutsopoulos V, Wilsher N, Arroo RRJ and Potter GA: Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett 274: 54-60, 2009.
11. Browning AM, Walle UK and Walle T: Flavonoid glycosides inhibit oral cancer cell proliferation - role of cellular uptake and hydrolysis to the aglycones. J Pharm Pharmacol 57: 1037-1042, 2005.
12. Ciolino HP, Wang TTY and Yeh GC: Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res 58: 2754-2760, 1998.
13. Doostdar H, Burke MD and Mayer RT: Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144: 31-38, 2000.
14. Lim do Y, Jeong Y, Tyner AL and Park JH: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol 292: G66-G75, 2007.
15. Casagrande F and Darbon JM: Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol 61: 1205-1215, 2001.
16. Chang J, Hsu Y, Kuo P, Kuo Y, Chiang L and Lin C: Increase of Bax/Bcl-XL ratio and arrest of cell cycle by luteolin in immortalised human hepatoma cell line. Life Sci 76: 1883-1893, 2005.
17. Huang YT, Hwang JJ, Lee PP, Ke FC, Huang JH, Huang CJ, Kandaswami C, Middleton E and Lee MT: Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells over-expressing epidermal growth factor receptor. Br J Pharmacol 128: 999-1010, 1999.
18. Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, Fox LH, Dickens M, Prigent SA and Manson MM: Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 65: 361-376, 2003.
19. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V and Cittadini A: Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 201: 97-105, 204.
20. Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC and Milano G: Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. Br J Cancer 89: 585-592, 2003.